Metraipolis › archive › dc_18fc2f763f13

Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells — Europe PMC PMID:41221272

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41221272
DOI
10.3389/fimmu.2025.1711448
License (as archived)
solo-consultazione
Archived
2026-11-09T01:04:57.866Z
SHA-256 of the archived text
07337d6d96d97abf2305e3b954ca3ba0827c976f12d61f0ae35536425779f049
Stable URL of this page
https://metraipolis.com/documento/dc_18fc2f763f13

How to cite

Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells — Europe PMC PMID:41221272 — Europe PMC (en), https://europepmc.org/article/MED/41221272 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_18fc2f763f13 (Metraipolis archive dc_18fc2f763f13, sha256 07337d6d96d97abf2305e3b954ca3ba0827c976f12d61f0ae35536425779f049)
BibTeX
@misc{dc18fc2f763f13,
  title = {Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells — Europe PMC PMID:41221272},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41221272},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_18fc2f763f13; sha256 07337d6d96d97abf2305e3b954ca3ba0827c976f12d61f0ae35536425779f049},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41221272. Agents can read the archived copy with the MCP tool read_document.